ePrints

Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial

Lookup NU author(s): Dr Janet Grace, Sarah Daniel, Professor Ian McKeith

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Patients with dementia with Lewy bodies (DLB) have progressive deficits in cognition, parkinsonism, and neuropsychiatric symptoms. Cholinesterase inhibitors have been used to ameliorate cognitive decline and neuropsychiatric symptoms in short-term trials. In this study, patients with DLB were treated with rivastigmine up to 96 weeks. Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) over the first 24 weeks of treatment. By 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.

Publication metadata

Author(s): Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, McKeith IG

Publication type: Article

Publication status: Published

Journal: International Psychogeriatrics

Year: 2001

Volume: 13

Issue: 2

Pages: 199-205

ISSN (print): 1041-6102

ISSN (electronic): 1741-203X

Publisher: International Psychogeriatric Association and Cambridge University Press

URL: http://dx.doi.org/10.1017/S104161020100758X

DOI: 10.1017/S104161020100758X

Altmetrics

Share